Sionna Therapeutics, Inc.
NASDAQ:SIONBiotechnology
+$0.68 today
- Market cap
- $134.35M
- Beta
- 1.29
- P/E (TTM)
- -19.7
- EPS (TTM)
- -$1.90
Volume 0.52M
Average 0.39M
SION Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Sionna Therapeutics, Inc.NASDAQ: SION
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income growth accelerates
Q1 FY2026 net income of $26.78M (cash outflow) rose 62.5% year over year, ahead of the +29.0% change in trailing-twelve-month net income. Sequentially, it rose 31.0% from the prior quarter. Over 3 fiscal years it compounded at +23.2% a year.
Context
- Net income grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether net income reaches the consensus estimate of -$117.85M (+56.6%) for the fiscal year ending Dec 2026, a step up from the +22.0% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$26.78M+31.0% QoQ
- Last fiscal yearDec 2025
- -$75.27M+22.0% YoY
- LTMMar 2026
- -$85.57M+29.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +62.5% | +61.6% | -0.9 pp |
| 1 year | +22.0% | +56.6% | +34.6 pp |
| 3-year CAGR | +23.2% | +17.3% | -5.9 pp |
| 5-year CAGR | +6.6% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (75.27M) USD
- Year-over-year change
- -22.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (75.27M) | -22.0% |
| FY2024 | 2024-12-31 | (61.69M) | -30.5% |
| FY2023 | 2023-12-31 | (47.26M) | -17.5% |
| FY2022 | 2022-12-31 | (40.24M) | — |
Net Income vs competitors
How SION compares with its peers on the latest reported figures
- SION's LTM Mar 2026 net income of $85.57M is the 8th largest of the 11 companies compared; the peer median is $157M.
- Its year-over-year change of +29.0% is the 6th highest of 11, against a peer median of +32.3%.
- Over three fiscal years its annual growth of +23.2% compares with a peer median of +21.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $586.84M | -23.5% | +9.0% | — | |
| LTM Jun 2026 | $401.9M | +84.1% | +49.8% | — | |
| LTM Sep 2026 | $309.06M | +37.6% | +32.1% | 275948.2% | |
| LTM Sep 2026 | $282.65M | +26.9% | +79.2% | — | |
| LTM Sep 2026 | $191.46M | +11.5% | — | 282.2% | |
| LTM Mar 2026 | $122.54M | -335.9% | +4.5% | 612.7% | |
| LTM Mar 2026 | $114.48M | +47.3% | +21.7% | 529.7% | |
| LTM Mar 2026 | $85.57M | +29.0% | +23.2% | — | |
| LTM Mar 2026 | $58.06M | +8.0% | -2.9% | 13.6% | |
| LTM Sep 2026 | $43.31M | +168.3% | — | 16.3% | |
| LTM Mar 2026 | $12.01M | +126.6% | — | 3.8% | |
| Peer median (excluding SION) | $157M | +32.3% | +21.7% | 282.2% | |
Competitors are the stored peer set for SION. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Sionna Therapeutics, Inc.
NASDAQ:SION
Intrinsic Alpha fair value
Locked
Current Price
$2.97
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.